CCLA Investment Management Has $113.10 Million Stock Holdings in Stryker Co. (NYSE:SYK)

CCLA Investment Management boosted its holdings in Stryker Co. (NYSE:SYK - Free Report) by 4.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 314,087 shares of the medical technology company's stock after buying an additional 14,186 shares during the period. Stryker makes up about 1.8% of CCLA Investment Management's investment portfolio, making the stock its 28th largest position. CCLA Investment Management owned about 0.08% of Stryker worth $113,099,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. Parnassus Investments LLC bought a new stake in shares of Stryker during the third quarter valued at approximately $762,798,000. International Assets Investment Management LLC boosted its stake in Stryker by 66,967.5% in the 3rd quarter. International Assets Investment Management LLC now owns 853,769 shares of the medical technology company's stock valued at $308,433,000 after buying an additional 852,496 shares in the last quarter. RTW Investments LP acquired a new stake in Stryker in the 3rd quarter valued at $143,392,000. State Street Corp boosted its stake in Stryker by 2.2% in the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company's stock valued at $5,279,788,000 after buying an additional 316,404 shares in the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Stryker by 49.8% in the 2nd quarter. Canada Pension Plan Investment Board now owns 686,416 shares of the medical technology company's stock valued at $233,553,000 after buying an additional 228,139 shares in the last quarter. 77.09% of the stock is owned by institutional investors.

Stryker Trading Up 1.5 %

Shares of Stryker stock traded up $5.29 during trading hours on Wednesday, hitting $368.09. The company's stock had a trading volume of 1,529,215 shares, compared to its average volume of 1,313,268. Stryker Co. has a 12 month low of $307.23 and a 12 month high of $398.20. The stock has a 50 day moving average of $375.13 and a 200 day moving average of $358.25. The company has a market capitalization of $140.32 billion, a PE ratio of 39.45, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.91 and a quick ratio of 1.22.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.10. Stryker had a return on equity of 23.07% and a net margin of 16.34%. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same period in the prior year, the company earned $2.46 earnings per share. The company's revenue for the quarter was up 11.9% compared to the same quarter last year. Analysts predict that Stryker Co. will post 12.06 earnings per share for the current year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. This is a boost from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. The ex-dividend date is Tuesday, December 31st. Stryker's dividend payout ratio is currently 36.01%.

Analysts Set New Price Targets

A number of equities analysts have commented on SYK shares. BTIG Research boosted their price objective on Stryker from $383.00 to $394.00 and gave the stock a "buy" rating in a research note on Wednesday, October 30th. Evercore ISI boosted their price objective on Stryker from $380.00 to $384.00 and gave the stock an "outperform" rating in a research note on Wednesday, October 30th. Wells Fargo & Company boosted their price objective on Stryker from $405.00 to $427.00 and gave the stock an "overweight" rating in a research note on Wednesday, December 11th. Canaccord Genuity Group upped their price target on Stryker from $360.00 to $400.00 and gave the company a "buy" rating in a research note on Wednesday, October 30th. Finally, Morgan Stanley raised Stryker from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $370.00 to $445.00 in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company's stock. According to data from MarketBeat, Stryker has an average rating of "Moderate Buy" and a consensus price target of $405.80.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.90% of the stock is owned by insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.